Dr. Axel Grothey highlighted metastatic colorectal cancer advances. Kairos 6 showed a 17% 5-year DFS gain from perioperative chemo. CheckMate 8HW and ANCHOR trials showed 34% reduced progression with nivolumab+ipilimumab and encorafenib+cetuximab. Future focus: targeting RAS mutations with pan-RAS inhibitors.